Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes

Young Ae KangTae Sun ShimWon-Jung KohSeung Heon LeeChang-Hoon LeeJae Chol ChoiJae Ho LeeSeung Hun JangKwang Ha YooKi Hwan JungKi Uk KimSang Bong ChoiYon Ju RyuKyung Chan KimSoojung UmYong-Soo KwonYee Hyung KimWon-Il ChoiKyeongman Jeon Yong Il Hwang9, Se Joong Kim8, Hyun-Kyung Lee19, Eunyoung Heo5, and Jae-Joon Yim
Dept. of Internal Medicine (내과학)
Issue Date
Annals of the American Thoracic Society, Vol.13(3) : 364-370, 2016
Rationale: We previously showed that the choice of levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB) did not affect sputumculture conversion at 3 months of treatment. Objectives: To compare final treatment outcomes between patients with MDR-TB randomized to levofloxacin or moxifloxacin. Methods: A total of 151 participants with MDR-TB who were included for the final analysis in our previous trial were followed through the end of treatment. Treatment outcomes were compared between 77 patients in the levofloxacin group and 74 in the moxifloxacin group, based on the 2008 World Health Organization definitions as well as 2013 revised definitions of treatment outcomes. In addition, the time to culture conversion was compared between the two groups. Measurements and Main Results: Treatment outcomes were not different between the two groups, based on 2008 World Health Organization definitions as well as 2013 definitions. With 2008 definitions, cure was achieved in 54 patients (70.1%) in the levofloxacin group and 54 (73.0%) in the moxifloxacin group (P = 0.72). Treatment success rates, including cure and treatment completed, were not different between the two groups (87.0 vs. 81.1%, P = 0.38). With 2013 definitions, cure rates (83.1 vs. 78.4%, P = 0.54) and treatment success rates (84.4 vs. 79.7%, P = 0.53) were also similar between the levofloxacin and moxifloxacin groups. Time to culture conversion was also not different between the two groups (27.0 vs. 45.0 d, P = 0.11 on liquid media; 17.0 vs. 42.0 d, P = 0.14 on solid media). Patients in the levofloxacin group had more adverse events than those in the moxifloxacin group (79.2 vs. 63.5%, P = 0.03), especially musculoskeletal ones (37.7 vs. 14.9%, P = 0.001). Conclusions: The choice of levofloxacin or moxifloxacin made no difference to the final treatment outcome among patients with fluoroquinolone-sensitiveMDR-TB. Clinical trial registered with (NCT01055145).
Multidrug-resistant tuberculosisFluoroquinolonesMoxifloxacinLevofloxacin
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
Full Text
File in this Item
 사서에게 요청하기
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.